ARKG · BATS · ETF
ARK Genomic Revolution ETF (ARKG) Price, Holdings & Fees
ARK Genomic Revolution ETF (ARKG) closed at $687.98 on Oct 9, 2026, up 0.51% from the previous close of $684.49.
Share price, past year
1Y +16.98%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $687.98 |
| Sep 30, 2026 | $702.52 |
| Aug 31, 2026 | $690.92 |
| Jul 31, 2026 | $728.50 |
| Jun 30, 2026 | $739.41 |
| May 29, 2026 | $817.84 |
| Apr 30, 2026 | $790.44 |
| Mar 31, 2026 | $715.43 |
| Feb 27, 2026 | $721.01 |
| Jan 30, 2026 | $674.76 |
| Dec 31, 2025 | $693.75 |
| Nov 28, 2025 | $645.24 |
| Oct 31, 2025 | $587.41 |
Key statistics
- Expense ratio
- 0.75%
- as of Jul 31, 2025
- Net assets
- $1.6B
- as of Jul 31, 2026
- Holdings
- 33
- as of Jul 31, 2026
- 52-week range
- $573.13 – $832.64
ARK Genomic Revolution ETF's expense ratio is 0.75%: $75.00 a year on $10,000 invested.
Holdings
ARK Genomic Revolution ETF held 33 investments worth $1.56B as of Jul 31, 2026. Its largest holding was 10X GENOMICS INC, at 9.39% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | 10X GENOMICS INCTXG | 9.39% | $146.30M |
| 2 | TWIST BIOSCIENCE CORPTWST | 7.73% | $120.36M |
| 3 | TEMPUS AI INCTEM | 6.56% | $102.18M |
| 4 | CRISPR THERAPEUTICS AGCRSP | 6.29% | $97.88M |
| 5 | PERSONALIS INCPSNL | 5.47% | $85.25M |
| 6 | ABSCI CORPABSI | 5.14% | $80.04M |
| 7 | GUARDANT HEALTH INCGH | 4.74% | $73.85M |
| 8 | ILLUMINA INCILMN | 4.74% | $73.80M |
| 9 | ELI LILLY & COMPANYLLY | 4.68% | $72.95M |
| 10 | CAREDX INCCDNA | 4.30% | $66.95M |
| 11 | NATERA INCNTRA | 4.13% | $64.30M |
| 12 | BEAM THERAPEUTICS INCBEAM | 3.78% | $58.82M |
| 13 | COMPASS PATHWAYS PLCCMPS | 3.25% | $50.66M |
| 14 | RECURSION PHARMACEUTICALS INCRXRX | 2.63% | $40.92M |
| 15 | ADAPTIVE BIOTECHNOLOGIES CORPADPT | 2.57% | $40.06M |
| 16 | VERACYTE INCVCYT | 2.55% | $39.66M |
| 17 | NURIX THERAPEUTICS INCNRIX | 2.51% | $39.04M |
| 18 | BUTTERFLY NETWORK INCBFLY | 2.18% | $33.92M |
| 19 | SCHRODINGER INCSDGR | 1.99% | $30.92M |
| 20 | GENEDX HOLDINGS CORPWGS | 1.87% | $29.10M |
| 21 | INTELLIA THERAPEUTICS INCNTLA | 1.83% | $28.48M |
| 22 | IONIS PHARMACEUTICALS INCIONS | 1.77% | $27.52M |
| 23 | ALAMAR BIOSCIENCES INCALMR | 1.56% | $24.27M |
| 24 | PRIME MEDICINE INCPRME | 1.41% | $21.94M |
| 25 | GENERATE BIOMEDICINES INCGENB | 1.11% | $17.33M |
Top 25 of 33 holdings, as of Jul 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 99.63% |
| Cash and short-term investments | 0.18% |
| Country | % of fund |
|---|---|
| United States | 90.27% |
| Switzerland | 6.29% |
| United Kingdom | 3.25% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jul 31, 2026, ARK Genomic Revolution ETF's total return was +29.12%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jul 31, 2026 | −8.30% |
| Jun 30, 2026 | +21.56% |
| May 31, 2026 | +15.83% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- ARK Genomic Revolution ETF
- Ticker
- ARKG
- Exchange
- BATS
- Fund type
- ETF
- Trust
- ARK ETF Trust
- SEC series ID
- S000042975
- SEC CIK
- 0001579982
- Fractional shares
- Yes
Recent SEC filings
- Sep 22, 2026
- Oct 7, 2026
- 485BPOSProspectus updateJul 27, 2026
- Apr 9, 2026
- 485BPOSProspectus updateNov 26, 2025
- Oct 8, 2025
- 485BPOSProspectus updateSep 25, 2025
- Apr 7, 2025
Shareholder reports and prospectuses are filed by ARK ETF Trust, the trust behind ARK Genomic Revolution ETF, and cover all of its funds.
Frequently asked questions
What is ARKG's price?
ARK Genomic Revolution ETF (ARKG) closed at $687.98 on Oct 9, 2026, up 0.51% from the previous close of $684.49.
What is ARKG's expense ratio?
ARK Genomic Revolution ETF's expense ratio is 0.75%: $75.00 a year on $10,000 invested.
What does ARKG hold?
ARK Genomic Revolution ETF held 33 investments worth $1.56B as of Jul 31, 2026. Its largest holding was 10X GENOMICS INC, at 9.39% of the fund. Its five largest holdings were 10X GENOMICS INC, TWIST BIOSCIENCE CORP, TEMPUS AI INC, CRISPR THERAPEUTICS AG, PERSONALIS INC.
How has ARKG performed?
Over the 3 months to Jul 31, 2026, ARK Genomic Revolution ETF's total return was +29.12%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jul 31, 2026 (filed Sep 22, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jul 31, 2025. Prices are generated sample data for development. Data sources and disclosures